APPRISE Oncology Program for Erythropoiesis-Stimulating Agents

Area of Science:

• Oncology
• Pharmacovigilance
• Drug Safety

Background:

• Erythropoiesis-stimulating agents (ESAs) are crucial in managing anemia associated with cancer and chemotherapy.
• Previous safety concerns have necessitated enhanced regulatory oversight for ESAs.
• The FDA requires specific risk management strategies for certain medications.

Purpose of the Study:

• To announce and describe the FDA's oncology-specific Risk Evaluation and Mitigation Strategy (REMS) for ESAs.
• To introduce the APPRISE program as the framework for this REMS.
• To outline the objectives and components of the APPRISE program.

Main Methods:

• The FDA announced the APPRISE program.
• The program is an oncology-specific REMS.
• It applies to ESAs prescribed under approved indications.

Main Results:

• The FDA has established a new regulatory framework for ESA use in oncology.
• The APPRISE program is now the designated REMS for these agents.
• This strategy focuses on approved indications within cancer treatment.

Conclusions:

• The APPRISE program represents a significant regulatory update for ESA use in cancer patients.
• This initiative underscores the FDA's commitment to drug safety in oncology.
• Healthcare providers should familiarize themselves with the APPRISE program requirements.